source
- Skyhawk reports functional gains in Huntington's disease trial of RNA-splicing pillSkyhawk Therapeutics, a Boston biotech backed by Fidelity, released final data from a small mid-stage trial of its once-daily RNA-splicing pill for Huntington's disease. After 15 months, patients…
- Sling Therapeutics raises $123M Series C to advance oral thyroid eye disease drugSling Therapeutics raised $123 million in a Series C financing round to move its oral drug candidate for thyroid eye disease forward. The capital will fund development of linsitinib, the only late…